HK1257518A1 - 針對人白介素-2的免疫刺激性人源化單克隆抗體及其融合蛋白 - Google Patents
針對人白介素-2的免疫刺激性人源化單克隆抗體及其融合蛋白Info
- Publication number
- HK1257518A1 HK1257518A1 HK18116440.2A HK18116440A HK1257518A1 HK 1257518 A1 HK1257518 A1 HK 1257518A1 HK 18116440 A HK18116440 A HK 18116440A HK 1257518 A1 HK1257518 A1 HK 1257518A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- stimulating
- immune
- monoclonal antibodies
- fusion proteins
- antibodies against
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/246—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662277113P | 2016-01-11 | 2016-01-11 | |
PCT/IB2017/050127 WO2017122130A1 (en) | 2016-01-11 | 2017-01-11 | Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1257518A1 true HK1257518A1 (zh) | 2019-10-25 |
Family
ID=57882113
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18116440.2A HK1257518A1 (zh) | 2016-01-11 | 2018-12-21 | 針對人白介素-2的免疫刺激性人源化單克隆抗體及其融合蛋白 |
Country Status (14)
Country | Link |
---|---|
US (2) | US10889643B2 (zh) |
EP (1) | EP3402819A1 (zh) |
JP (1) | JP6993699B2 (zh) |
KR (1) | KR20180100224A (zh) |
CN (2) | CN108473569B (zh) |
AU (1) | AU2017208133B2 (zh) |
BR (1) | BR112018014150A2 (zh) |
CA (1) | CA3009001A1 (zh) |
EA (1) | EA039865B1 (zh) |
HK (1) | HK1257518A1 (zh) |
IL (1) | IL260218B2 (zh) |
MA (1) | MA43859A (zh) |
MX (1) | MX2018008592A (zh) |
WO (1) | WO2017122130A1 (zh) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
CN106103484B (zh) * | 2014-03-14 | 2021-08-20 | 诺华股份有限公司 | 针对lag-3的抗体分子及其用途 |
BR112018008904A2 (pt) | 2015-11-03 | 2018-11-27 | Janssen Biotech Inc | anticorpos que se ligam especificamente a tim-3 e seus usos |
AU2017214277B2 (en) * | 2016-02-01 | 2020-02-27 | Eli Lilly And Company | Parathyroid hormone – anti-RANKL antibody fusion compounds |
CA3038679A1 (en) * | 2016-09-28 | 2018-04-05 | Xoma (Us) Llc | Antibodies that bind interleukin-2 and uses thereof |
WO2018170288A1 (en) | 2017-03-15 | 2018-09-20 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
BR112019024127A2 (pt) | 2017-05-24 | 2020-06-23 | Pandion Therapeutics, Inc. | Imunotolerância alvejada |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
US20190225689A1 (en) * | 2018-01-22 | 2019-07-25 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-pd-1 antibodies |
WO2019168791A2 (en) * | 2018-02-28 | 2019-09-06 | The Board Of Trustees Of The Leland Stanford Junior University | Single-chain il-2/antibody fusions that selectively activate regulatory t cells |
US20210238558A1 (en) * | 2018-06-01 | 2021-08-05 | Medicenna Therapeutics, Inc. | Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof |
KR20220035333A (ko) | 2019-05-20 | 2022-03-22 | 팬디온 오퍼레이션스, 인코포레이티드 | Madcam 표적 면역관용 |
KR102627471B1 (ko) * | 2020-02-16 | 2024-01-18 | 아울로스 바이오사이언스 인코포레이티드 | 조작된 항-il-2 항체 |
CN111825763B (zh) * | 2020-07-15 | 2022-04-19 | 扬州大学 | 流感病毒ha蛋白茎部特异性单克隆抗体及其制备方法和应用 |
WO2022200525A1 (en) | 2021-03-26 | 2022-09-29 | Innate Pharma | Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging |
WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
CN117616050A (zh) | 2021-06-09 | 2024-02-27 | 先天制药公司 | 与nkp46、细胞因子受体、肿瘤抗原和cd16a结合的多特异性蛋白质 |
US11773160B1 (en) * | 2022-08-05 | 2023-10-03 | Anaveon AG | Immune-stimulating IL-2 fusion proteins |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE434680B (sv) | 1983-01-21 | 1984-08-06 | Karl Arne Lundblad | Anvendning av en saltlosning av monoklonala antikroppar med relativt hog salthalt vid blodgruppsbestemning |
US4708871A (en) | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
NZ210634A (en) | 1983-12-23 | 1989-05-29 | Hoffmann La Roche | Purification of recombinant human interleukin - 2; pharmaceutical compositions |
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
DE68925966T2 (de) | 1988-12-22 | 1996-08-29 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
FR2686901A1 (fr) | 1992-01-31 | 1993-08-06 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant. |
FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
DE69731289D1 (de) | 1996-03-18 | 2004-11-25 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
US6111090A (en) | 1996-08-16 | 2000-08-29 | Schering Corporation | Mammalian cell surface antigens; related reagents |
EP1947183B1 (en) | 1996-08-16 | 2013-07-17 | Merck Sharp & Dohme Corp. | Mammalian cell surface antigens; related reagents |
WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
US6673901B2 (en) | 1997-06-12 | 2004-01-06 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
US6689607B2 (en) | 1997-10-21 | 2004-02-10 | Human Genome Sciences, Inc. | Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2 |
JP2001520039A (ja) | 1997-10-21 | 2001-10-30 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | ヒト腫瘍壊死因子レセプター様タンパク質、tr11,tr11sv1およびtr11sv2 |
CA2319236A1 (en) | 1998-02-09 | 1999-08-12 | Genentech, Inc. | Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same |
ATE376837T1 (de) | 1999-07-12 | 2007-11-15 | Genentech Inc | Stimulierung oder hemmung von angiogenese und herzvaskularisierung mit tumor nekrose faktor ligand/rezeptor homologen |
EP1276849A4 (en) | 2000-04-12 | 2004-06-09 | Human Genome Sciences Inc | ALBUMIN FUSION PROTEINS |
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
JP4511943B2 (ja) | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Pd−1に対する抗体およびその使用 |
CA2511538C (en) | 2002-12-30 | 2013-11-26 | 3M Innovative Properties Company | Immunostimulatory combinations |
CA2525717A1 (en) | 2003-05-23 | 2004-12-09 | Wyeth | Gitr ligand and gitr ligand-related molecules and antibodies and uses thereof |
EP1660126A1 (en) | 2003-07-11 | 2006-05-31 | Schering Corporation | Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer |
WO2005055808A2 (en) | 2003-12-02 | 2005-06-23 | Genzyme Corporation | Compositions and methods to diagnose and treat lung cancer |
GB0409799D0 (en) | 2004-04-30 | 2004-06-09 | Isis Innovation | Method of generating improved immune response |
WO2006083289A2 (en) | 2004-06-04 | 2006-08-10 | Duke University | Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
EP1866339B8 (en) | 2005-03-25 | 2021-12-01 | GITR, Inc. | Gitr binding molecules and uses therefor |
LT2439273T (lt) | 2005-05-09 | 2019-05-10 | Ono Pharmaceutical Co., Ltd. | Žmogaus monokloniniai antikūnai prieš programuotos mirties 1(pd-1) baltymą, ir vėžio gydymo būdai, naudojant vien tik anti-pd-1 antikūnus arba derinyje su kitais imunoterapiniais vaistais |
NZ563213A (en) | 2005-06-01 | 2009-07-31 | Micromet Ag | Anti-IL2 antibodies |
WO2006138315A2 (en) | 2005-06-15 | 2006-12-28 | Schering Corporation | Anti-igf1r antibody formulations |
CN102875681A (zh) | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | 抗-αvβ6抗体及其用途 |
EP1981969A4 (en) | 2006-01-19 | 2009-06-03 | Genzyme Corp | ANTI-GITRANT ANTIBODIES FOR THE TREATMENT OF CANCER |
MX2008010562A (es) | 2006-02-15 | 2009-03-05 | Imclone Systems Inc | Formulacion de anticuerpo. |
EP1987065A4 (en) * | 2006-02-16 | 2010-01-20 | Nascent Biolog Inc | METHOD FOR IMPROVING THE IMMUNE FUNCTION AND METHOD FOR PREVENTING OR TREATING DISEASES IN MAMMALS |
DK2170959T3 (da) | 2007-06-18 | 2014-01-13 | Merck Sharp & Dohme | Antistoffer mod human programmeret dødsreceptor pd-1 |
ES2591281T3 (es) | 2007-07-12 | 2016-11-25 | Gitr, Inc. | Terapias de combinación que emplean moléculas de enlazamiento a GITR |
BRPI0907718A2 (pt) | 2008-02-11 | 2017-06-13 | Curetech Ltd | método para tratar um tumor, método para melhorar a tolerabilidade a pelo menos um agente quimiterápico, método para aumentar a sobrevida de um indivíduo que tem um tumor, método para reduzir ou prevenir recidiva tumoral, uso de um anticorpo monoclonal humanizado ou seu fragmento e anticorpo monoclonal humanizado ou seu fragmento |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
KR20110044992A (ko) | 2008-07-02 | 2011-05-03 | 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 | TGF-β 길항제 다중-표적 결합 단백질 |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
NZ591130A (en) | 2008-08-25 | 2012-09-28 | Amplimmune Inc | Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof |
US20110159023A1 (en) | 2008-08-25 | 2011-06-30 | Solomon Langermann | Pd-1 antagonists and methods for treating infectious disease |
CN102149820B (zh) | 2008-09-12 | 2014-07-23 | 国立大学法人三重大学 | 能够表达外源gitr配体的细胞 |
LT3023438T (lt) | 2009-09-03 | 2020-05-11 | Merck Sharp & Dohme Corp. | Anti-gitr antikūnai |
GB0919054D0 (en) | 2009-10-30 | 2009-12-16 | Isis Innovation | Treatment of obesity |
JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Pd−l1/pd−l2の同時阻害 |
SI2519543T1 (sl) | 2009-12-29 | 2016-08-31 | Emergent Product Development Seattle, Llc | Beljakovine, ki se vežejo s heterodimeri in njihova uporaba |
TR201807750T4 (tr) | 2010-06-11 | 2018-06-21 | Kyowa Hakko Kirin Co Ltd | Anti-TIM-3 antikoru. |
CN103068848B (zh) | 2010-08-12 | 2015-11-25 | 伊莱利利公司 | 抗N3pGlu淀粉样蛋白BETA肽抗体及其用途 |
PE20140303A1 (es) | 2011-02-10 | 2014-03-22 | Roche Glycart Ag | Polipeptidos interleuquina-2 mutantes |
WO2013039954A1 (en) | 2011-09-14 | 2013-03-21 | Sanofi | Anti-gitr antibodies |
JP2015514421A (ja) | 2012-04-17 | 2015-05-21 | ザ ユニバーシティ オブ ワシントン スルー イッツ センター フォーコマーシャライゼーションThe University Of Washington Through Its Center For Commercialization | Hlaクラスiiタンパク質の発現能を有するhlaクラスii欠損細胞、hlaクラスi欠損細胞、及びその使用 |
WO2013157105A1 (ja) | 2012-04-18 | 2013-10-24 | 公立大学法人大阪市立大学 | ムチンサブタイプ5ac特異的ヒト化抗体およびその利用 |
KR101566539B1 (ko) | 2012-06-08 | 2015-11-05 | 국립암센터 | 신규한 Th2 세포 전환용 에피토프 및 이의 용도 |
AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
CN112587658A (zh) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
AU2014268836B2 (en) | 2013-05-18 | 2018-08-02 | Aduro Biotech, Inc. | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
CN105188373B (zh) | 2013-05-18 | 2017-09-22 | 艾杜罗生物科技公司 | 抑制“干扰素基因刺激蛋白”依赖性信号传导的组合物和方法 |
AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
WO2015109212A1 (en) | 2014-01-17 | 2015-07-23 | Pfizer Inc. | Anti-il-2 antibodies and compositions and uses thereof |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
CN106103484B (zh) | 2014-03-14 | 2021-08-20 | 诺华股份有限公司 | 针对lag-3的抗体分子及其用途 |
EP3166973B1 (en) | 2014-07-10 | 2020-02-19 | Universität Zürich | Immune-stimulating monoclonal antibodies against human interleukin-2 |
-
2017
- 2017-01-11 KR KR1020187023058A patent/KR20180100224A/ko unknown
- 2017-01-11 US US16/069,146 patent/US10889643B2/en active Active
- 2017-01-11 WO PCT/IB2017/050127 patent/WO2017122130A1/en active Application Filing
- 2017-01-11 JP JP2018536134A patent/JP6993699B2/ja active Active
- 2017-01-11 MX MX2018008592A patent/MX2018008592A/es unknown
- 2017-01-11 EP EP17701362.0A patent/EP3402819A1/en active Pending
- 2017-01-11 AU AU2017208133A patent/AU2017208133B2/en active Active
- 2017-01-11 CA CA3009001A patent/CA3009001A1/en active Pending
- 2017-01-11 IL IL260218A patent/IL260218B2/en unknown
- 2017-01-11 EA EA201891582A patent/EA039865B1/ru unknown
- 2017-01-11 CN CN201780006001.9A patent/CN108473569B/zh active Active
- 2017-01-11 BR BR112018014150A patent/BR112018014150A2/pt unknown
- 2017-01-11 MA MA043859A patent/MA43859A/fr unknown
- 2017-01-11 CN CN202211356161.5A patent/CN116003593A/zh active Pending
-
2018
- 2018-12-21 HK HK18116440.2A patent/HK1257518A1/zh unknown
-
2020
- 2020-12-17 US US17/124,930 patent/US11851484B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2017122130A1 (en) | 2017-07-20 |
CN108473569B (zh) | 2022-11-22 |
JP6993699B2 (ja) | 2022-02-03 |
KR20180100224A (ko) | 2018-09-07 |
IL260218B (en) | 2022-12-01 |
BR112018014150A2 (pt) | 2018-12-11 |
CN108473569A (zh) | 2018-08-31 |
EP3402819A1 (en) | 2018-11-21 |
EA201891582A1 (ru) | 2018-12-28 |
US11851484B2 (en) | 2023-12-26 |
IL260218A (en) | 2018-07-31 |
US20190016797A1 (en) | 2019-01-17 |
MA43859A (fr) | 2018-11-21 |
AU2017208133A1 (en) | 2018-07-05 |
US20210246200A1 (en) | 2021-08-12 |
JP2019511200A (ja) | 2019-04-25 |
MX2018008592A (es) | 2018-12-10 |
CA3009001A1 (en) | 2017-07-20 |
AU2017208133B2 (en) | 2023-12-21 |
IL260218B2 (en) | 2023-04-01 |
EA039865B1 (ru) | 2022-03-22 |
US10889643B2 (en) | 2021-01-12 |
WO2017122130A9 (en) | 2018-02-01 |
CN116003593A (zh) | 2023-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1257518A1 (zh) | 針對人白介素-2的免疫刺激性人源化單克隆抗體及其融合蛋白 | |
EP3621642A4 (en) | HUMAN MONOCLONAL ANTIBODIES AGAINST LAG3 AND THEIR USES | |
SG11202001368SA (en) | Antigen-binding proteins tatrgeting shared antigens | |
EP3470427A4 (en) | MONOCLONAL INTERLEUKIN-17A HUMAN ANTIBODIES, PREPARATION METHOD AND USE THEREOF | |
EP3505535A4 (en) | MONOCLONAL ANTI-PD-1 ANTIBODY, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | |
IL262092A (en) | Human anti-pacap antibodies and their use | |
IL262173B (en) | Antibodies, antibody fragments and their immunomodules against axl and their uses | |
ZA201701920B (en) | Anti-human il-17 monoclonal antibodies and use thereof | |
EP3411069A4 (en) | HUMANIZED ANTI-CD3 ANTIBODIES, CONJUGATES AND USES THEREOF | |
ZA201908072B (en) | Igf-1r monoclonal antibodies and uses thereof | |
IL276978A (en) | Antibodies against IL-6 and their fusions and conjugates | |
IL283104A (en) | Antagonist monoclonal CD40 antibodies and their use | |
IL280757A (en) | Monoclonal antibodies against human TIM-3 | |
IL262404A (en) | Antibodies, antibody fragments, and their immunosuppressants against ror2 and their uses | |
IL291545A (en) | Antibodies against ctla4, antibody fragments, their immunoconjugates and their uses | |
EP3846850A4 (en) | HUMANIZED ANTI-C5 ANTIBODIES AND THEIR USES | |
ZA202003858B (en) | Monoclonal antibodies and methods for using same | |
IL281608A (en) | Antibodies against human CD45RC and their use | |
SG11202103095RA (en) | Anti-human vsig4 antibodies and uses thereof | |
IL266769A (en) | Monoclonal antibodies specific for fgfr1 and their preparation | |
EP3722311A4 (en) | HUMAN ANTI-IL6 MONOCLONAL ANTIBODIES, METHOD FOR THE PREPARATION AND USE THEREOF | |
GB201911211D0 (en) | Monoclonal antibodies against ambra-1 | |
EP3712270A4 (en) | MONOCLONAL ANTIBODY AND USES THEREOF | |
EP3893930A4 (en) | MONOCLONAL ANTIBODIES AGAINST HUMAN DICKKOPF3 AND THEIR USES | |
EP3634476A4 (en) | HUMANIZED ANTI-N-CADHERIN ANTIBODIES AND THEIR USES |